Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis.

Two SARS-CoV-2 variants of concern showing increased transmissibility relative to the Wuhan virus have recently been identified. Although neither variant appears to cause more severe illness nor increased risk of death, the faster spread of the virus is a major threat. Using computational tools, we found that the new SARS-CoV-2 variants may acquire an increased transmissibility by increasing the propensity of its spike protein to expose the receptor binding domain via proteolysis, perhaps by neutrophil elastase and/or via reduced intramolecular interactions that contribute to the stability of the closed conformation of spike protein. This information leads to the identification of potential treatments to avert the imminent threat of these more transmittable SARS-CoV-2 variants

Peripheral Sensitization Increases Opioid Receptor Expression And Activation By Crotalphine In Rats

Inflammation enhances the peripheral analgesic efficacy of opioid drugs, but the mechanisms involved in this phenomenon have not been fully elucidated. Crotalphine (CRP), a peptide that was first isolated from South American rattlesnake C.d. terrificus venom, induces a potent and long-lasting anti-nociceptive effect that is mediated by the activation of peripheral opioid receptors. Because the high efficacy of CRP is only observed in the presence of inflammation, we aimed to elucidate the mechanisms involved in the CRP anti-nociceptive effect induced by inflammation. Using real-time RT-PCR, western blot analysis and ELISA assays, we demonstrate that the intraplantar injection of prostaglandin E2 (PGE2) increases the mRNA and protein levels of the μ- and κ-opioid receptors in the dorsal root ganglia (DRG) and paw tissue of rats within 3 h of the injection. Using conformation state-sensitive antibodies that recognize activated opioid receptors, we show that PGE 2, alone does not increase the activation of these opioid receptors but that in the presence of PGE2, the activation of specific opioid receptors by CRP and selective μ- and κ-opioid receptor agonists (positive controls) increases. Furthermore, PGE2 down-regulated the expression and activation of the δ-opioid receptor. CRP increased the level of activated mitogen-activated protein kinases in cultured DRG neurons, and this increase was dependent on the activation of protein kinase Cζ. This CRP effect was much more prominent when the cells were pretreated with PGE 2. These results indicate that the expression and activation of peripheral opioid receptors by opioid-like drugs can be up- or down-regulated in the presence of an acute injury and that acute tissue injury enhances the efficacy of peripheral opioids. © 2014 Zambelli et al.93Stein, C., Peripheral mechanisms of opioid analgesia (1993) Anesth Analg, 76, pp. 182-191Obara, I., Parkitna, J.R., Korostynski, M., Makuch, W., Kaminska, D., Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain (2009) Pain, 141, pp. 283-291Puehler, W., Zollner, C., Brack, A., Shaqura, M.A., Krause, H., Schafer, M., Stein, C., Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction (2004) Neuroscience, 129 (2), pp. 473-479. , DOI 10.1016/j.neuroscience.2004.06.086, PII S030645220400627XMaekawa, K., Minami, M., Masuda, T., Satoh, M., Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats (1996) Pain, 64 (2), pp. 365-371. , DOI 10.1016/0304-3959(95)00132-8Cahill, C.M., Morinville, A., Hoffert, C., O'Donnell, D., Beaudet, A., Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: Implications for pain control (2003) Pain, 101 (1-2), pp. 199-208. , DOI 10.1016/S0304-3959(02)00333-0Hassan, A.H.S., Ableitner, A., Stein, C., Herz, A., Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue (1993) Neuroscience, 55 (1), pp. 185-195. , DOI 10.1016/0306-4522(93)90465-RZollner, C., Shaqura, M.A., Bopaiah, C.P., Mousa, S., Stein, C., Schafer, M., Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons (2003) Molecular Pharmacology, 64 (2), pp. 202-210. , DOI 10.1124/mol.64.2.202Shaqura, M.A., Zollner, C., Mousa, S.A., Stein, C., Schafer, M., Characterization of mu Opioid Receptor Binding and G Protein Coupling in Rat Hypothalamus, Spinal Cord, and Primary Afferent Neurons during Inflammatory Pain (2004) Journal of Pharmacology and Experimental Therapeutics, 308 (2), pp. 712-718. , DOI 10.1124/jpet.103.057257Antonijevic, I., Mousa, S.A., Schafer, M., Stein, C., Perineurial defect and peripheral opioid analgesia in inflammation (1995) J Neurosci, 15, pp. 165-172Mousa, S.A., Zhang, Q., Sitte, N., Ji, R.-R., Stein, C., beta-endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue (2001) Journal of Neuroimmunology, 115 (1-2), pp. 71-78. , DOI 10.1016/S0165-5728(01)00271-5, PII S0165572801002715Konno, K., Picolo, G., Gutierrez, V.P., Brigatte, P., Zambelli, V.O., Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus (2008) PeptidesGutierrez, V.P., Zambelli, V.O., Picolo, G., Chacur, M., Sampaio, S.C., The peripheral L-arginine-nitric oxide-cyclic GMP pathway and ATP-sensitive K channels are involved in the antinociceptive effect of crotalphine on neuropathic pain in rats Behav Pharmacol, 23, pp. 14-24Gutierrez, V.P., Konno, K., Chacur, M., Sampaio, S.C., Picolo, G., Crotalphine induces potent antinociception in neuropathic pain by acting at peripheral opioid receptors (2008) Eur J Pharmacol, 594, pp. 84-92Granados-Soto, V., Rufino, M.D.O., Gomes, L.L.D., Ferreira, S.H., Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin tests (1997) European Journal of Pharmacology, 340 (2-3), pp. 177-180. , DOI 10.1016/S0014-2999(97)01399-X, PII S001429999701399XSachs, D., Cunha, F.Q., Ferreira, S.H., Peripheral analgesic blockade of hypernociception: Activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (10), pp. 3680-3685. , DOI 10.1073/pnas.0308382101Pacheco, D.F., Reis, G.M.L., Francischi, J.N., Castro, M.S.A., Perez, A.C., Duarte, I.D.G., delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta1 and delta2 receptors and activation of the L-arginine/nitric oxide/cyclic GMP pathway (2005) Life Sciences, 78 (1), pp. 54-60. , DOI 10.1016/j.lfs.2005.04.032, PII S0024320505006697Amarante, L.H., Duarte, I.D.G., The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway (2002) European Journal of Pharmacology, 454 (1), pp. 19-23. , DOI 10.1016/S0014-2999(02)02275-6, PII S0014299902022756Cunha, T.M., Roman-Campos, D., Lotufo, C.M., Duarte, H.L., Souza, G.R., Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway Proc Natl Acad Sci U S A, 107, pp. 4442-4447Law, B.K., Waltner-Law, M.E., Entingh, A.J., Chytil, A., Aakre, M.E., Norgaard, P., Moses, H.L., Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-Myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen (2000) Journal of Biological Chemistry, 275 (49), pp. 38261-38267. , DOI 10.1074/jbc.M005545200Belcheva, M.M., Clark, A.L., Haas, P.D., Serna, J.S., Hahn, J.W., Kiss, A., Coscia, C.J., Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes (2005) Journal of Biological Chemistry, 280 (30), pp. 27662-27669. , DOI 10.1074/jbc.M502593200Connor, M., Christie, M.J., Opioid receptor signalling mechanisms (1999) Clinical and Experimental Pharmacology and Physiology, 26 (7), pp. 493-499. , DOI 10.1046/j.1440-1681.1999.03049.xZimmermann, M., Ethical guidelines for investigations of experimental pain in conscious animals (1983) Pain, 16, pp. 109-110Picolo, G., Giorgi, R., Bernardi, M.M., Cury, Y., The antinociceptive effect of Crotalus durissus terrificus snake venom is mainly due to a supraspinally integrated response (1998) Toxicon, 36 (1), pp. 223-227. , DOI 10.1016/S0041-0101(97)00048-2, PII S0041010197000482Von Banchet, G.S., Scholze, A., Schaible, H.-G., Prostaglandin E2 increases the expression of the neurokinin1 receptor in adult sensory neurones in culture: A novel role of prostaglandins (2003) British Journal of Pharmacology, 139 (3), pp. 672-680Picolo, G., Giorgi, R., Cury, Y., delta-Opioid receptors and nitric oxide mediate the analgesic effect of Crotalus durissus terrificus snake venom (2000) European Journal of Pharmacology, 391 (1-2), pp. 55-62. , DOI 10.1016/S0014-2999(99)00934-6, PII S0014299999009346Gendron, L., Pintar, J.E., Chavkin, C., Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia (2007) Neuroscience, 150 (4), pp. 807-817. , DOI 10.1016/j.neuroscience.2007.09.060, PII S0306452207012365Lomas, L.M., Barrett, A.C., Terner, J.M., Lysle, D.T., Picker, M.J., Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats (2007) Psychopharmacology, 191 (2), pp. 273-285. , DOI 10.1007/s00213-006-0663-1Ji, Y., Murphy, A.Z., Traub, R.J., Estrogen modulation of morphine analgesia of visceral pain in female rats is supraspinally and peripherally mediated (2007) J Pain, 8, pp. 494-502. , JPicolo, G., Cury, Y., Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta- and kappa-opioid receptor agonist (2004) Life Sciences, 75 (5), pp. 559-573. , DOI 10.1016/S0024-3205(04)00292-9, PII S0024320504002929Randall, L.O., Selitto, J.J., A method for measurement of analgesia activity on inflamed tissue (1957) Arch Inst Pharmacodyn, 111, pp. 209-219Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal Biochem, 72, pp. 248-254Gupta, A., Decaillot, F.M., Gomes, I., Tkalych, O., Heimann, A.S., Conformation state sensitive antibodies to G-protein coupled receptors (2006) J Biol ChemCunha, T.M., Souza, G.R., Domingues, A.C., Carreira, E.U., Lotufo, C.M., Stimulation of peripheral Kappa opioid receptors inhibits inflammatory hyperalgesia via activation of the PI3Kgamma/AKT/nNOS/NO signaling pathway Mol Pain, 8, p. 10Bruchas, M.R., Chavkin, C., Kinase cascades and ligand-directed signaling at the kappa opioid receptor Psychopharmacology, 210, pp. 137-147. , BerlBerra, E., Diaz-Meco, M.T., Dominguez, I., Municio, M.M., Sanz, L., Lozano, J., Chapkin, R.S., Moscat, J., Protein kinase C zeta isoform is critical for mitogenic signal transduction (1993) Cell, 74 (3), pp. 555-563Kwong, K., Lee, L.-Y., Prostaglandin E2 potentiates a TTX-resistant sodium current in rat capsaicin-sensitive vagal pulmonary sensory neurones (2005) Journal of Physiology, 564 (2), pp. 437-450. , DOI 10.1113/jphysiol.2004.078725Southall, M.D., Vasko, M.R., Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons (2001) J Biol Chem, 276, pp. 16083-16091Ferreira, S.H., Lorenzetti, B.B., Prostaglandin hyperalgesia, IV: A metabolic process (1981) Prostaglandins, 21, pp. 789-792Stein, C., Millan, M.J., Shippenberg, T.S., Peter, K., Herz, A., Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors (1989) Journal of Pharmacology and Experimental Therapeutics, 248 (3), pp. 1269-1275Mousa, S.A., Machelska, H., Schafer, M., Stein, C., Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain (2002) Journal of Neuroimmunology, 126 (1-2), pp. 5-15. , DOI 10.1016/S0165-5728(02)00049-8, PII S0165572802000498Furst, S., Riba, P., Friedmann, T., Timar, J., Al-Khrasani, M., Obara, I., Makuch, W., Schmidhammer, H., Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat (2005) Journal of Pharmacology and Experimental Therapeutics, 312 (2), pp. 609-618. , DOI 10.1124/jpet.104.075176Nunez, S., Lee, J.-S., Zhang, Y., Bai, G., Ro, J.Y., Role of peripheral mu-opioid receptors in inflammatory orofacial muscle pain (2007) Neuroscience, 146 (3), pp. 1346-1354. , DOI 10.1016/j.neuroscience.2007.02.024, PII S030645220700173XSchafer, M., Imai, Y., Uhl, G.R., Stein, C., Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia (1995) Eur J Pharmacol, 279, pp. 165-169Zhou, L., Zhang, Q., Stein, C., Schafer, M., Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia (1998) Journal of Pharmacology and Experimental Therapeutics, 286 (2), pp. 1000-1006Lecat, S., Bucher, B., Mely, Y., Galzi, J.-L., Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses (2002) Journal of Biological Chemistry, 277 (44), pp. 42034-42048. , DOI 10.1074/jbc.M203606200Decaillot, F.M., Befort, K., Filliol, D., Yue, S.Y., Walker, P., Kieffer, B.L., Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation (2003) Nature Structural Biology, 10 (8), pp. 629-636. , DOI 10.1038/nsb950Selley, D.E., Breivogel, C.S., Childers, S.R., Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: Increase in opioid agonist efficacy by decreased inactivation of G proteins (1993) Molecular Pharmacology, 44 (4), pp. 731-741Belcheva, M.M., Vogel, Z., Ignatova, E., Avidor-Reiss, T., Zippel, R., Levy, R., Young, E.C., Coscia, C.J., Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves G(betagamma) subunits (1998) Journal of Neurochemistry, 70 (2), pp. 635-645Bohn, L.M., Belcheva, M.M., Coscia, C.J., Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: Evidence for the involvement of protein kinase C and the mitogen- activated protein kinase signaling cascade (2000) Journal of Neurochemistry, 74 (2), pp. 564-573. , DOI 10.1046/j.1471-4159.2000.740564.xBruchas, M.R., Macey, T.A., Lowe, J.D., Chavkin, C., Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes (2006) Journal of Biological Chemistry, 281 (26), pp. 18081-18089. , http://www.jbc.org/cgi/reprint/281/26/18081, DOI 10.1074/jbc.M513640200Sweatt, J.D., Mitogen-activated protein kinases in synaptic plasticity and memory (2004) Curr Opin Neurobiol, 14, pp. 311-317Thomas, G.M., Huganir, R.L., MAPK cascade signalling and synaptic plasticity (2004) Nature Reviews Neuroscience, 5 (3), pp. 173-183Carlezon Jr., W.A., Duman, R.S., Nestler, E.J., The many faces of CREB (2005) Trends in Neurosciences, 28 (8), pp. 436-445. , DOI 10.1016/j.tins.2005.06.005, PII S016622360500158XBruchas, M.R., Xu, M., Chavkin, C., Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2 (2008) Neuroreport, 19, pp. 1417-1422Kreibich, A.S., Blendy, J.A., cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement (2004) Journal of Neuroscience, 24 (30), pp. 6686-6692. , DOI 10.1523/JNEUROSCI.1706-04.2004Bruchas, M.R., Yang, T., Schreiber, S., DeFino, M., Kwan, S.C., Li, S., Chavkin, C., Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase (2007) Journal of Biological Chemistry, 282 (41), pp. 29803-29811. , http://www.jbc.org/cgi/reprint/282/41/29803, DOI 10.1074/jbc.M705540200Melief, E.J., Miyatake, M., Bruchas, M.R., Chavkin, C., Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling (2010) Proc Natl Acad Sci U S A, 107, pp. 11608-11613Velazquez, K.T., Mohammad, H., Sweitzer, S.M., Protein kinase C in pain: Involvement of multiple isoforms (2007) Pharmacological Research, 55 (6), pp. 578-589. , DOI 10.1016/j.phrs.2007.04.006, PII S104366180700084

Small‐Molecule Activators of Glucose‐6‐phosephate Dehydrogenase (G6PD) Bridging the Dimer Interface

We have recently identified AG1, a small-molecule activator that functions by promoting oligomerization of glucose-6- phosphate dehydrogenase (G6PD) to the catalytically competent forms. Biochemical experiments indicate activation of G6PD by the original hit molecule (AG1) is noncovalent and that one C2-symmetric region of the G6PD homodimer is important for ligand function. Consequently, the disulfide in AG1 is not required for activation of G6PD and a number of analogs were prepared without this reactive moiety. Our Study supports a mechanism of action whereby AG1 bridges the dimer interface at the structural nicotinamide adenine dinucleotide phosphate (NADP+)-binding sites of two interacting G6PD monomers. Small molecules that promote G6PD oligomerization have the potential to provide a first-in-class treatment for G6PD deficiency. This general strategy could be applied to other enzyme deficiencies where control of oligomerization can enhance enzymatic activity and/or stability

Mouse Sphingosine Kinase 1a Is Negatively Regulated through Conventional PKC-Dependent Phosphorylation at S373 Residue

Sphingosine kinase is a lipid kinase that converts sphingosine into sphingosine-1-phosphate, an important signaling molecule with intracellular and extracellular functions. Although diverse extracellular stimuli influence cellular sphingosine kinase activity, the molecular mechanisms underlying its regulation remain to be clarified. In this study, we investigated the phosphorylation-dependent regulation of mouse sphingosine kinase (mSK) isoforms 1 and 2. mSK1a was robustly phosphorylated in response to extracellular stimuli such as phorbol ester, whereas mSK2 exhibited a high basal level of phosphorylation in quiescent cells regardless of agonist stimulation. Interestingly, phorbol ester-induced phosphorylation of mSK1a correlated with suppression of its activity. Chemical inhibition of conventional PKCs (cPKCs) abolished mSK1a phosphorylation, while overexpression of PKC alpha, a cPKC isoform, potentiated the phosphorylation, in response to phorbol ester. Furthermore, an in vitro kinase assay showed that PKC alpha directly phosphorylated mSK1a. In addition, phosphopeptide mapping analysis determined that the S373 residue of mSK1a was the only site phosphorylated by cPKC. Interestingly, alanine substitution of S373 made mSK1a refractory to the inhibitory effect of phorbol esters, whereas glutamate substitution of the same residue resulted in a significant reduction in mSK1a activity, suggesting the significant role of this phosphorylation event. Taken together, we propose that mSK1a is negatively regulated through cPKC-dependent phosphorylation at S373 residueopen

Ischaemic preconditioning improves proteasomal activity and increases the degradation of δPKC during reperfusion

The response of the myocardium to an ischaemic insult is regulated by two highly homologous protein kinase C (PKC) isozymes, delta and epsilon PKC. Here, we determined the spatial and temporal relationships between these two isozymes in the context of ischaemia/reperfusion (I/R) and ischaemic preconditioning (IPC) to better understand their roles in cardioprotection. Using an ex vivo rat model of myocardial infarction, we found that short bouts of ischaemia and reperfusion prior to the prolonged ischaemic event (IPC) diminished delta PKC translocation by 3.8-fold and increased epsilon PKC accumulation at mitochondria by 16-fold during reperfusion. In addition, total cellular levels of delta PKC decreased by 60 +/- 2.7% in response to IPC, whereas the levels of epsilon PKC did not significantly change. Prolonged ischaemia induced a 48 +/- 11% decline in the ATP-dependent proteasomal activity and increased the accumulation of misfolded proteins during reperfusion by 192 +/- 32%; both of these events were completely prevented by IPC. Pharmacological inhibition of the proteasome or selective inhibition of epsilon PKC during IPC restored delta PKC levels at the mitochondria while decreasing epsilon PKC levels, resulting in a loss of IPC-induced protection from I/R. Importantly, increased myocardial injury was the result, in part, of restoring a delta PKC-mediated I/R pro-apoptotic phenotype by decreasing pro-survival signalling and increasing cytochrome c release into the cytosol. Taken together, our findings indicate that IPC prevents I/R injury at reperfusion by protecting ATP-dependent 26S proteasomal function. This decreases the accumulation of the pro-apoptotic kinase, delta PKC, at cardiac mitochondria, resulting in the accumulation of the pro-survival kinase, epsilon PKC.NIH[AA11147]Oklahoma Center for Advancement of Science and Technology[HR05-171S

Protein kinase C and cardiac dysfunction: a review

Heart failure (HF) is a physiological state in which cardiac output is insufficient to meet the needs of the body. It is a clinical syndrome characterized by impaired ability of the left ventricle to either fill or eject blood efficiently. HF is a disease of multiple aetiologies leading to progressive cardiac dysfunction and it is the leading cause of deaths in both developed and developing countries. HF is responsible for about 73,000 deaths in the UK each year. In the USA, HF affects 5.8 million people and 550,000 new cases are diagnosed annually. Cardiac remodelling (CD), which plays an important role in pathogenesis of HF, is viewed as stress response to an index event such as myocardial ischaemia or imposition of mechanical load leading to a series of structural and functional changes in the viable myocardium. Protein kinase C (PKC) isozymes are a family of serine/threonine kinases. PKC is a central enzyme in the regulation of growth, hypertrophy, and mediators of signal transduction pathways. In response to circulating hormones, activation of PKC triggers a multitude of intracellular events influencing multiple physiological processes in the heart, including heart rate, contraction, and relaxation. Recent research implicates PKC activation in the pathophysiology of a number of cardiovascular disease states. Few reports are available that examine PKC in normal and diseased human hearts. This review describes the structure, functions, and distribution of PKCs in the healthy and diseased heart with emphasis on the human heart and, also importantly, their regulation in heart failure

Protein kinase C in heart failure: a therapeutic target?

Heart failure (HF) afflicts about 5 million people and causes 300 000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to causes of HF, such as ischaemia, myocardial infarction, volume and pressure overload, infection, inflammation, and mechanical injury. These responses, including cardiomyocyte hypertrophy, myocardial fibrosis, and inflammation, involve numerous cellular and structural changes and ultimately result in a progressive decline in cardiac performance. Pharmacological and genetic manipulation of cultured heart cells and animal models of HF and the analysis of cardiac samples from patients with HF are all used to identify the molecular and cellular mechanisms leading to the disease. Protein kinase C (PKC) isozymes, a family of serine–threonine protein kinase enzymes, were found to regulate a number of cardiac responses, including those associated with HF. In this review, we describe the PKC isozymes that play critical roles in specific aspects of cardiac remodelling and dysfunction in HF

Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.

UNLABELLED: COVID-19 emergency use authorizations and approvals for vaccines were achieved in record time. However, there remains a need to develop additional safe, effective, easy-to-produce, and inexpensive prevention to reduce the risk of acquiring SARS-CoV-2 infection. This need is due to difficulties in vaccine manufacturing and distribution, vaccine hesitancy, and, critically, the increased prevalence of SARS-CoV-2 variants with greater contagiousness or reduced sensitivity to immunity. Antibodies from eggs of hens (immunoglobulin Y; IgY) that were administered the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were developed for use as nasal drops to capture the virus on the nasal mucosa. Although initially raised against the 2019 novel coronavirus index strain (2019-nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had indistinguishable enzyme-linked immunosorbent assay binding against variants of concern that have emerged, including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529). This is different from sera of immunized or convalescent patients. Culture neutralization titers against available Alpha, Beta, and Delta were also indistinguishable from the index SARS-CoV-2 strain. Efforts to develop these IgY for clinical use demonstrated that the intranasal anti-SARS-CoV-2 RBD IgY preparation showed no binding (cross-reactivity) to a variety of human tissues and had an excellent safety profile in rats following 28-day intranasal delivery of the formulated IgY. A double-blind, randomized, placebo-controlled phase 1 study evaluating single-ascending and multiple doses of anti-SARS-CoV-2 RBD IgY administered intranasally for 14 days in 48 healthy adults also demonstrated an excellent safety and tolerability profile, and no evidence of systemic absorption. As these antiviral IgY have broad selectivity against many variants of concern, are fast to produce, and are a low-cost product, their use as prophylaxis to reduce SARS-CoV-2 viral transmission warrants further evaluation. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov/ct2/show/NCT04567810, identifier NCT04567810